The average tumor weight of mice receiving AFP-Cre/LoxP-shRNA-Atg5 plus sorafenib (1.04±0.33) was significantly lower than that of mice subjected to sorafenib alone (1.42±0.29) (P = 0.039) (Fig. 5D). Here, ATG5 is linked to neoplasm.